Breaking News

Gilead To License Hep C Drug in India

Will allow for lower-cost versions of new drug Sovaldi

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead Sciences plans to license its hepatitis C drug Sovaldi to several Indian generic pharmaceutical manufacturers, allowing for lower-cost versions of the drug in India. According to the company, final details of the program in India will be released in the next few months. The company also has a similar program in place for its HIV/AIDS drugs.   Company spokesman Nick Francis said, “Gilead aims to establish tiered pricing. Providing treatment in resource-limited settings presents complex cha...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters